Group items tagged

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate. The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.    

This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function system development and function; and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases. Each P01 application submitted to this FOA must include at least two related research projects that share a common central theme, focus, and/or overall objective.  

The National Library of Medicine (NLM) offers support for innovative research in biomedical informatics and data science. The scope of NLM's interest in the research domain of informatics is broad and interdisciplinary, developing methods and approaches in biomedical computing, data science and related information fields for application domains of health and biomedicine, including health care delivery, basic biomedical research, clinical and translational research, precision medicine, public health, biosurveillance, health information management in disasters, and similar areas. NLM defines biomedical informatics as the science of optimal representation, organization, management, integration and presentation of information relevant to human health and biology, for purposes of learning, sharing and use.

The purpose of this funding opportunity announcement (FOA) is to support innovative, multidisciplinary, interactive, and synergistic program projects that integrate basic, translational, and clinical approaches to understanding the developmental biology and genetic basis of significant congenital human malformations. To contain costs, each program project will consist of only three component research projects, as well as associated cores. At least one project must use basic research in an animal model system and at least one project must be clinical or translational in nature. The component research projects must share a common central theme, focus, or objective on a specific major developmental defect or malformation that is genotypically, mechanistically, biologically, or phenotypically analogous or homologous in both animal models and humans. Any non-mammalian or mammalian animal model may be used, as long as it contributes to the common overall theme or objective of the program project.  The component research projects should share a common developmental gene, process, mechanism, pathway, or phenotype.

The U.S. Environmental Protection Agency (EPA), through its Science to Achieve Results (STAR) program, seeks applications for research on how pollution affects human health in the context of the total environment - built, natural, and social environments interacting together with inherent characteristics and interactions. Proposed research should develop and test innovative models or impact assessment approaches to examine causal relationships of chemical pollutants and health effects with modifying interactions among the variables representing all of the major stressors and factors involved in a person's life. Proposals that integrate a diverse field of disciplines (social science, economics, epidemiology, engineering, environmental science, biology, statistics, toxicology, chemistry, etc.) to address the complexity of the total environment research problem are highly recommended.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status.

This Funding Opportunity Announcement (FOA) invites grant applications for Environmental Health Sciences Core Centers (EHS CC).  As intellectual hubs for environmental health research, the EHS CC is expected to be the thought leaders for the field and advance the goals of the NIEHS Strategic Plan (http://www.niehs.nih.gov/about/strategicplan/). The Core Centers provide critical research infrastructure, shared facilities, services and /or resources, to groups of investigators conducting environmental health sciences research.  An EHS CC enables researchers to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively. The broad overall goal of an EHS CC is to identify and capitalize on emerging issues that advance improving the understanding of the relationships among environmental exposures, human biology, and disease.  The EHS CC supports community engagement and translational research as key approaches to improving public health. 

The objective of this research career program is to create a national Consortium that focuses on career development of the next generation of biomedical investigators in glycosciences. The ultimate goal of the Consortium is to transform and democratize glycosciences from a super-specialized research domain into the mainstream of biology and clinical translation such that glycans become an integral component of future scholars'/investigators' scientific thinking, thus creating a pathway for major scientific breakthroughs specifically in heart, lung, blood and sleep (HLBS) sciences.    

Pathway supports innovative basic, clinical, translational, epidemiological, behavioral, or health services research relevant to any diabetes type, diabetes-related disease state, or diabetes complication. The Association seeks exceptional candidates from a broad range of disciplines, including medicine, biology, chemistry, computing, physics, mathematics and engineering.

Through its Science of Hope and Optimism Funding Initiative program, the association will award two-year grants of up to $250,000 for research projects that use a variety of methods to explore the nature of hope and optimism. Priority will be given to projects in cognitive, developmental, personality, health, and social psychology, as well as sociology. Interdisciplinary teams that include members from cognate areas - e.g., cognitive science, anthropology, nursing, and biology - are encouraged.

The purpose of this Funding Opportunity Announcement (FOA) and the companion FOA is to solicit applications for computational and functional analysis of gene networks and complex pathways that confer susceptibility to severe mental illnesses. These studies should leverage existing diverse multi-scale datasets and apply a combination of cutting-edge bioinformatics, computational predictive modeling, and systems biology approaches to identify and begin to evaluate novel genetic factors and molecular networks underlying functional pathways relevant to psychiatric disorders to verify their relationship or causality with disease/disease risk.  The computational model predictions should be further replicated through independent datasets and confirmed using biological measures from existing and/or new experimental data.

The goal of this Funding Opportunity Announcement (FOA) is to support novel basic and translational research projects that focus on the biology of residual oral reservoirs for HIV and opportunistic oral pathogens.These studies will advance our understanding of the immunologic, pathogenic, molecular and cellular mechanisms important for eliminating latently persistent, reactivation competent HIV and other opportunistic pathogens from residual oral reservoirs.Specifically, this FOA encourages studies on: 1) purging and abolishing these pathogens after using Highly Active Anti-Retroviral Therapy (HAART) to induce cytopathic killing and immunoclearance; or 2) developing alternative strategies that directly eliminate latently infected cells in which HAART resistant HIV and opportunistic pathogens persist in oral reservoirs.

The goal of this Funding Opportunity Announcement (FOA) is to support novel basic and translational research projects that focus on the biology of residual oral reservoirs for HIV and opportunistic oral pathogens.  These studies will advance our understanding of the immunologic, pathogenic, molecular and cellular mechanisms important for eliminating latently persistent, reactivation competent HIV and other opportunistic pathogens from residual oral reservoirs.  Specifically, this FOA encourages studies on: 1) purging and abolishing these pathogens after using Highly Active Anti-Retroviral Therapy (HAART) to induce cytopathic killing and immunoclearance; or 2) developing alternative strategies that directly eliminate latently infected cells in which HAART resistant HIV and opportunistic pathogens persist in oral reservoirs.

Through the program, grants of $50,000 per year for up to two years will be awarded to junior investigators on the path to independence for research on the mechanisms and biology of interstitial lung disease.The Dalsemer Research Grant is for $50,000 per year, for up to two years. Grants are subjected to annual review and may be granted for two years. The second year of support is based on demonstrating satisfactory progress, as well as, the availability of funding from the Lung Association. Applicants should be on-track to pursue a career in lung heath research with a mentor who has a demonstrated history of lung disease research and mentorship.

This FOA aims to elucidate basic sleep and circadian mechanisms contributing to the risk of opiate use disorder (OUD), the pathobiology of opiate withdrawal, and that influence the response to medication-assisted treatment (MAT). Studies are needed to apply advances in understanding sleep and circadian biology to improving our understanding of OUD, the directionality of sleep and OUD interactions, and the opportunities to improve therapy and outcome. Multi-disciplinary, multiple-investigator teams combining expertise in sleep and circadian neurobiology with the neurobiology OUD and pharmacology of MAT are strongly encouraged. This FOA is only open to the study of OUD relevant mechanisms and pathobiology. The study of other drugs of abuse will not be responsive.

The purpose of this Funding Opportunity Announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety such as 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors (e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan).

The purpose of this Funding Opportunity Announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors (e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources, such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan).

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or following vaccination with Bacillus Calmette-Gurin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or uninfected individuals. Development of novel functional assays to assess host response and inclusion of immune profiling and systems biology approaches are encouraged. This FOA seeks to stimulate innovative research in deciphering immune mechanisms in humans required for protection from Mtb infection or tuberculosis (TB) disease, or induced by TB vaccines that go beyond what have traditionally been investigated in TB.

This funding Opportunity Announcement (FOA) encourages Multiple Principal Investigator (Multi-PD/PI) applications from United States (U.S.) and Indian institution as bilateral collaborations that will advance science and technology important to understanding, preventing, and treating blinding eye diseases, visual disorders, and their complications. Areas of Research Collaboration: Applications are encouraged from organization/institutions that propose to conduct research on the basic biology and/or genetics of ophthalmic diseases through collaborations with Indian investigators on the following: diabetic retinopathy, glaucoma, age-related macular degeneration, retinitis pigmentosa, including rare and genetic diseases such as congenital cataracts, as well as other eye conditions such as ocular inflammation/uveitis, refractive error, low vision, and corneal injury. Basic, translational, or epidemiological research maybe proposed. Clinical trials will not be supported under this FOA.